Table 2 Adverse events during Neoadjuvant Pembrolizumab plus Chemoradiotherapy and after surgery
Events | n (%) |
|---|---|
Events of any grade during neoadjuvant therapy (n = 140) | |
Blood and lymphatic system disorders | |
Lymphopenia | 119 (85.0) |
Leukopenia | 101 (72.1) |
Anemia | 80 (57.1) |
Thrombocytopenia | 64 (45.7) |
Decreased neutrophil count | 47 (33.6) |
Immune-related events | |
Pneumonitis | 4 (2.9) |
Myocarditis | 1 (0.7) |
Hepatitis | 1 (0.7) |
Pancreatitis | 1 (0.7) |
Toxic epidermal necrolysis | 1 (0.7) |
Gastrointestinal disorders | |
Nausea | 19 (13.6) |
Esophagitis | 16 (11.4) |
Vomiting | 12 (8.6) |
Constipation | 8 (5.7) |
Diarrhea | 6 (4.3) |
Esophageal hemorrhage | 3 (2.1) |
Skin and subcutaneous tissue disorders | |
Alopecia | 24 (17.1) |
Rash | 8 (5.7) |
Dermatitis | 7 (5.0) |
General disorders | |
Fatigue | 22 (15.7) |
Events of grade ≥ 3 during neoadjuvant therapy (n = 140) | |
Blood and lymphatic system disorders | |
Lymphopenia | 104 (74.3) |
Leukopenia | 4 (2.9) |
Anemia | 1 (0.7) |
Thrombocytopenia | 2 (1.4) |
Decreased neutrophil count | 2 (1.4) |
Immune-related events | |
Pneumonitis | 4 (2.9) |
Myocarditis | 1 (0.7) |
Hepatitis | 1 (0.7) |
Pancreatitis | 1 (0.7) |
Toxic epidermal necrolysis | 1 (0.7) |
Gastrointestinal disorders | |
Esophageal hemorrhage | 2 (1.4) |
Postoperative events (n = 125) | |
Pneumonia | 27 (21.6) |
Hoarseness | 21 (16.8) |
Anastomotic leakage | 14 (11.2) |
Chylothorax | 4 (3.2) |
Postoperative intrathoracic hemorrhage | 2 (1.6) |
Gastrointestinal fistula | 1 (0.8) |
Wound infection | 1 (0.8) |
Tracheoesophageal fistula | 1 (0.8) |
Cholecystitis | 1 (0.8) |
